{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "b65e1af7",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Requirement already satisfied: openai in /opt/anaconda3/lib/python3.12/site-packages (1.91.0)\n",
      "Requirement already satisfied: python-docx in /opt/anaconda3/lib/python3.12/site-packages (1.2.0)\n",
      "Requirement already satisfied: requests in /opt/anaconda3/lib/python3.12/site-packages (2.32.3)\n",
      "Requirement already satisfied: anyio<5,>=3.5.0 in /opt/anaconda3/lib/python3.12/site-packages (from openai) (4.2.0)\n",
      "Requirement already satisfied: distro<2,>=1.7.0 in /opt/anaconda3/lib/python3.12/site-packages (from openai) (1.9.0)\n",
      "Requirement already satisfied: httpx<1,>=0.23.0 in /opt/anaconda3/lib/python3.12/site-packages (from openai) (0.27.0)\n",
      "Requirement already satisfied: jiter<1,>=0.4.0 in /opt/anaconda3/lib/python3.12/site-packages (from openai) (0.10.0)\n",
      "Requirement already satisfied: pydantic<3,>=1.9.0 in /opt/anaconda3/lib/python3.12/site-packages (from openai) (2.8.2)\n",
      "Requirement already satisfied: sniffio in /opt/anaconda3/lib/python3.12/site-packages (from openai) (1.3.0)\n",
      "Requirement already satisfied: tqdm>4 in /opt/anaconda3/lib/python3.12/site-packages (from openai) (4.66.5)\n",
      "Requirement already satisfied: typing-extensions<5,>=4.11 in /opt/anaconda3/lib/python3.12/site-packages (from openai) (4.14.0)\n",
      "Requirement already satisfied: lxml>=3.1.0 in /opt/anaconda3/lib/python3.12/site-packages (from python-docx) (5.2.1)\n",
      "Requirement already satisfied: charset-normalizer<4,>=2 in /opt/anaconda3/lib/python3.12/site-packages (from requests) (3.3.2)\n",
      "Requirement already satisfied: idna<4,>=2.5 in /opt/anaconda3/lib/python3.12/site-packages (from requests) (3.7)\n",
      "Requirement already satisfied: urllib3<3,>=1.21.1 in /opt/anaconda3/lib/python3.12/site-packages (from requests) (2.2.3)\n",
      "Requirement already satisfied: certifi>=2017.4.17 in /opt/anaconda3/lib/python3.12/site-packages (from requests) (2024.8.30)\n",
      "Requirement already satisfied: httpcore==1.* in /opt/anaconda3/lib/python3.12/site-packages (from httpx<1,>=0.23.0->openai) (1.0.2)\n",
      "Requirement already satisfied: h11<0.15,>=0.13 in /opt/anaconda3/lib/python3.12/site-packages (from httpcore==1.*->httpx<1,>=0.23.0->openai) (0.14.0)\n",
      "Requirement already satisfied: annotated-types>=0.4.0 in /opt/anaconda3/lib/python3.12/site-packages (from pydantic<3,>=1.9.0->openai) (0.6.0)\n",
      "Requirement already satisfied: pydantic-core==2.20.1 in /opt/anaconda3/lib/python3.12/site-packages (from pydantic<3,>=1.9.0->openai) (2.20.1)\n"
     ]
    }
   ],
   "source": [
    "!pip install openai python-docx requests\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "5938fb59",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "âœ… Access token received\n"
     ]
    }
   ],
   "source": [
    "import requests\n",
    "\n",
    "# GSK OAuth URL and client credentials\n",
    "token_url = \"https://federation-qa.gsk.com/as/token.oauth2\"\n",
    "client_id = \"eb98c3a954444f91a887dc054dd2037c\"\n",
    "client_secret = \"XJJVX1bKrQ1YznWfzHunzVhTkQJP2I3wivNjBG2k2rJlHQNIDVV1AwL7TABtAZtcaMF4\"\n",
    "\n",
    "# Request token\n",
    "response = requests.post(\n",
    "    token_url,\n",
    "    data={\n",
    "        \"grant_type\": \"client_credentials\",\n",
    "        \"client_id\": client_id,\n",
    "        \"client_secret\": client_secret\n",
    "    }\n",
    ")\n",
    "\n",
    "# Parse token\n",
    "access_token = response.json()[\"access_token\"]\n",
    "print(\"âœ… Access token received\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "fd1c35c6",
   "metadata": {},
   "outputs": [],
   "source": [
    "# GSK Enterprise OpenAI Endpoint\n",
    "endpoint = \"https://dev.api.gsk.com/co/edap/openaidevtest02/openai/deployments/gpt-4o/chat/completions?api-version=2025-01-01-preview\"\n",
    "\n",
    "# Headers with OAuth token\n",
    "headers = {\n",
    "    \"Authorization\": f\"Bearer {access_token}\",\n",
    "    \"Content-Type\": \"application/json\"\n",
    "}\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "00c8a2e0",
   "metadata": {},
   "outputs": [],
   "source": [
    "import json\n",
    "\n",
    "def summarize_field(field, matched_paragraph):\n",
    "    prompt = f\"\"\"\n",
    "You are an AI assistant generating a summary for a clinical report.\n",
    "\n",
    "Summarize the following paragraph as a proper response to the field '{field}'.\n",
    "\n",
    "Paragraph:\n",
    "{matched_paragraph}\n",
    "\n",
    "Summary:\n",
    "\"\"\"\n",
    "\n",
    "    # Prepare payload\n",
    "    payload = {\n",
    "        \"messages\": [\n",
    "            {\"role\": \"user\", \"content\": prompt}\n",
    "        ],\n",
    "        \"temperature\": 0.5\n",
    "    }\n",
    "\n",
    "    # Send request to GSK OpenAI endpoint\n",
    "    response = requests.post(endpoint, headers=headers, data=json.dumps(payload))\n",
    "    result = response.json()\n",
    "\n",
    "    return result[\"choices\"][0][\"message\"][\"content\"].strip()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "50a53433",
   "metadata": {},
   "outputs": [],
   "source": [
    "import json\n",
    "\n",
    "# Load matched_paragraphs from semantic_matching.json (from Day 2 output)\n",
    "with open(\"matched_paragraphs.json\", \"r\") as f:\n",
    "    matched_paragraphs = json.load(f)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "ea503178",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "ğŸŸ© FIELD: Protocol Summary - Master Disclosure Document for Interventional Studies\n",
      "ğŸ” Matched Paragraph:\n",
      " 6.\tSTUDY INTERVENTION(S) AND CONCOMITANT THERAPY\t46\n",
      "ğŸ“ Summary:\n",
      " **Protocol Summary - Master Disclosure Document for Interventional Studies:**\n",
      "\n",
      "The study outlines the specific interventions administered to participants, detailing the primary investigational treatment(s) under evaluation. It also addresses guidelines for concomitant therapies, including permitted and prohibited medications or procedures that may be used alongside the study intervention. This section ensures standardized implementation of treatments and minimizes potential interference with study outcomes.\n",
      "\n",
      "ğŸŸ© FIELD: The Information on this page will not be posted\n",
      "ğŸ” Matched Paragraph:\n",
      " PAGE\n",
      "ğŸ“ Summary:\n",
      " This page contains clinical information intended for internal use only and will not be publicly disclosed or posted.\n",
      "\n",
      "ğŸŸ© FIELD: Before using this template for authoring, refer to the supplemental instructions on Find-IT. This template is used for ALL Interventional studies that evaluate the safety, efficacy or effectiveness of a GSK product.\n",
      "Master Disclosure Document (MDD) serves as the source document to disclose protocol related information across different clinical trial registers (e.g. ClinicalTrials.gov, EU Clinical Trials Information System (EU CTIS) and/or GSK/ViiV Clinical Study Register) as required by external regulations and/or GSK policy. Check in TMF for the latest version of the template before initiating a new MDD. As information from the approved MDD will be disclosed on publicly available clinical trial register(s) as required by applicable regulations and GSK policy, minimize inclusion of information that may be considered commercially confidential.\n",
      "ğŸ” Matched Paragraph:\n",
      " The key design elements of this protocol and results summaries will be posted on www.ClinicalTrials.gov and/or GSK Clinical Study Register in compliance with applicable regulations/GSK policy. GSK will aim to register protocols summaries prior to study start and target results summaries submission within 12 months of primary/ study completion date. Where external regulations require earlier disclosure, GSK will follow those timelines.\n",
      "ğŸ“ Summary:\n",
      " Key design elements of the protocol and results summaries will be disclosed on www.ClinicalTrials.gov and/or the GSK Clinical Study Register in accordance with applicable regulations and GSK policy. Protocol summaries will be registered prior to study initiation, and results summaries will be submitted within 12 months of the primary or study completion date, unless earlier disclosure is required by external regulations.\n",
      "\n",
      "ğŸŸ© FIELD: Title of study\n",
      "ğŸ” Matched Paragraph:\n",
      " STUDY DESIGN\n",
      "ğŸ“ Summary:\n",
      " \"Study Design: Overview of the methodology and framework used to conduct the clinical research, detailing the approach, population, interventions, and outcome measures.\"\n",
      "\n",
      "ğŸŸ© FIELD: Study identifier /CTMS number\n",
      "ğŸ” Matched Paragraph:\n",
      " STUDY DESIGN\n",
      "ğŸ“ Summary:\n",
      " The study is identified by the Clinical Trial Management System (CTMS) number [Insert CTMS number], which serves as its unique identifier within the research database.\n",
      "\n",
      "ğŸŸ© FIELD: European Union (EU) Clinical Trial Regulation (EU CTR) number (if applicable)\n",
      "ğŸ” Matched Paragraph:\n",
      " Providing oversight of the conduct of the study at the site and adherence to requirements of 21 Code of Federal Regulation (CFR), ICH guidelines, the IRB/IEC, European regulation 536/2014 for clinical studies (if applicable), and all other applicable local regulations\n",
      "ğŸ“ Summary:\n",
      " European regulation 536/2014 for clinical studies applies, if applicable.\n",
      "\n",
      "ğŸŸ© FIELD: Is this an Applicable Clinical Trial (ACT)?\n",
      "ğŸ” Matched Paragraph:\n",
      " The participant has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 3 months, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).\n",
      "ğŸ“ Summary:\n",
      " Yes, this is an Applicable Clinical Trial (ACT) as the participant has been involved in a clinical trial and received an investigational product within the specified timeframe prior to the first dosing day in the current study.\n",
      "\n",
      "ğŸŸ© FIELD: Trial registers where the study will be disclosed\n",
      "ğŸ” Matched Paragraph:\n",
      " STUDY ASSESSMENTS AND PROCEDURES\n",
      "ğŸ“ Summary:\n",
      " The study will be disclosed in relevant trial registers to ensure transparency and compliance with regulatory requirements. Specific trial registry platforms have not been mentioned in the provided text.\n",
      "\n",
      "ğŸŸ© FIELD: MDD version date\n",
      "ğŸ” Matched Paragraph:\n",
      " Dates of administration including start and end dates\n",
      "ğŸ“ Summary:\n",
      " Start and end dates of administration.\n",
      "\n",
      "ğŸŸ© FIELD: Approver:\n",
      "ğŸ” Matched Paragraph:\n",
      " 10.1.3.\tInformed consent process\t69\n",
      "ğŸ“ Summary:\n",
      " Approver: The informed consent process outlined in section 10.1.3 ensures that participants receive comprehensive information about the study, its procedures, risks, and benefits, allowing them to make an educated decision regarding their participation.\n",
      "\n",
      "ğŸŸ© FIELD: Clinical Lead/equivalent\n",
      "ğŸ” Matched Paragraph:\n",
      " Participant safety will be continuously monitored by the Sponsorâ€™s Medical Monitor, and designated Safety Lead (or delegate) throughout the study. Pertinent findings and conclusions are shared with the productâ€™s safety review team for review of the overall benefit-risk profile of the product.\n",
      "ğŸ“ Summary:\n",
      " Participant safety will be overseen by the Sponsorâ€™s Medical Monitor and designated Safety Lead (or delegate) throughout the study, with relevant findings shared with the productâ€™s safety review team to assess the benefit-risk profile.\n",
      "\n",
      "ğŸŸ© FIELD: Section # and Name of the field\n",
      "{Add section number and name}\n",
      "ğŸ” Matched Paragraph:\n",
      " Medical Monitor Name and Contact Information:\n",
      "ğŸ“ Summary:\n",
      " Section # and Name of the field: Medical Monitor Name and Contact Information  \n",
      "\n",
      "Summary: This section provides the name and contact details of the designated medical monitor responsible for overseeing clinical trial activities and addressing medical-related inquiries or concerns.\n",
      "\n",
      "ğŸŸ© FIELD: Unique Protocol ID\n",
      "ğŸ” Matched Paragraph:\n",
      " Protocol Title:\n",
      "ğŸ“ Summary:\n",
      " The field 'Unique Protocol ID' refers to the specific identifier assigned to this clinical study protocol for tracking and reference purposes. It ensures the study can be uniquely distinguished in databases and regulatory submissions.\n",
      "\n",
      "ğŸŸ© FIELD: Brief title\n",
      "ğŸ” Matched Paragraph:\n",
      " Brief Title:\n",
      "ğŸ“ Summary:\n",
      " Please provide the paragraph you would like me to summarize for the \"Brief Title\" field.\n",
      "\n",
      "ğŸŸ© FIELD: Acronym\n",
      "ğŸ” Matched Paragraph:\n",
      " LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS\n",
      "ğŸ“ Summary:\n",
      " List of abbreviations and definitions of terms used in the clinical report.\n",
      "\n",
      "ğŸŸ© FIELD: CTMS abbreviated title [EU only]\n",
      "ğŸ” Matched Paragraph:\n",
      " LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS\n",
      "ğŸ“ Summary:\n",
      " List of Abbreviations and Definitions of Terms\n",
      "\n",
      "ğŸŸ© FIELD: Official title of the trial\n",
      "ğŸ” Matched Paragraph:\n",
      " Brief Title:\n",
      "ğŸ“ Summary:\n",
      " The official title of the trial is not explicitly provided in the paragraph above. Please clarify or provide additional details for accurate summarization.\n",
      "\n",
      "ğŸŸ© FIELD: Secondary IDs\n",
      "ğŸ” Matched Paragraph:\n",
      " Secondary estimands\n",
      "ğŸ“ Summary:\n",
      " Secondary estimands refer to additional measures or outcomes assessed in the study to provide further insights beyond the primary estimand. These estimands often explore supplementary aspects of treatment effects, subpopulation analyses, or alternative endpoints to enhance the understanding of the intervention's impact.\n",
      "\n",
      "ğŸŸ© FIELD: Secondary ID type\n",
      "ğŸ” Matched Paragraph:\n",
      " Secondary estimands\n",
      "ğŸ“ Summary:\n",
      " Secondary estimands refer to additional measures or outcomes of interest that complement the primary estimand, providing further insights into the treatment effect or clinical study objectives.\n",
      "\n",
      "ğŸŸ© FIELD: Sponsor\n",
      "ğŸ” Matched Paragraph:\n",
      " Sponsor Signatory:\n",
      "ğŸ“ Summary:\n",
      " The sponsor signatory is responsible for overseeing and authorizing the clinical report, ensuring compliance with regulatory standards and the accuracy of the data presented.\n",
      "\n",
      "ğŸŸ© FIELD: Collaborators\n",
      "ğŸ” Matched Paragraph:\n",
      " Activity\n",
      "ğŸ“ Summary:\n",
      " **Collaborators:** The report highlights the involvement of multiple stakeholders, including healthcare professionals, researchers, and administrative staff, who contributed to the planning, execution, and analysis of the clinical activity. Their collective expertise ensured the study's accuracy and reliability.\n",
      "\n",
      "ğŸŸ© FIELD: Brief summary\n",
      "ğŸ” Matched Paragraph:\n",
      " Brief Title:\n",
      "ğŸ“ Summary:\n",
      " It appears that the paragraph provided is incomplete. Please provide the full text or additional information for me to generate a proper summary for the 'Brief summary' field.\n",
      "\n",
      "ğŸŸ© FIELD: Detailed description\n",
      "ğŸ” Matched Paragraph:\n",
      " Synopsis\n",
      "ğŸ“ Summary:\n",
      " **Detailed description:**  \n",
      "The section provides a concise overview of the clinical report, highlighting key findings, observations, and conclusions relevant to the case or study. It summarizes the essential details while omitting in-depth analysis or extended explanations.\n",
      "\n",
      "ğŸŸ© FIELD: Main objective(s) [EU only]\n",
      "ğŸ” Matched Paragraph:\n",
      " Objectives, Endpoints, and Estimands:\n",
      "ğŸ“ Summary:\n",
      " The main objective is to evaluate the efficacy, safety, and tolerability of the investigational treatment in the target population, measured through predefined clinical endpoints and estimands to ensure robust and reliable analysis.\n",
      "\n",
      "ğŸŸ© FIELD: Secondary objective(s) [EU only]\n",
      "ğŸ” Matched Paragraph:\n",
      " OBJECTIVES, ENDPOINTS AND ESTIMANDS\n",
      "ğŸ“ Summary:\n",
      " Secondary objectives include evaluating additional clinical outcomes, safety measures, and exploratory endpoints to further characterize the treatment's effects and support the primary objectives.\n",
      "\n",
      "ğŸŸ© FIELD: Data monitoring committee\n",
      "ğŸ” Matched Paragraph:\n",
      " Data Monitoring/Other Committee:\n",
      "ğŸ“ Summary:\n",
      " The Data Monitoring Committee (DMC) is responsible for overseeing the safety and efficacy of the study, ensuring participant protection, and evaluating interim data to guide recommendations on trial continuation, modification, or termination. The DMC operates independently of the study team and adheres to predefined protocols to maintain objectivity and integrity in decision-making.\n",
      "\n",
      "ğŸŸ© FIELD: Keywords\n",
      "ğŸ” Matched Paragraph:\n",
      " REFERENCES\n",
      "ğŸ“ Summary:\n",
      " Keywords: References, citations, source material, bibliography, documentation.\n",
      "\n",
      "ğŸŸ© FIELD: Medical condition(s) investigated [EU only]\n",
      "ğŸ” Matched Paragraph:\n",
      " Abnormal laboratory findings associated with the underlying disease are not considered clinically significant unless judged by the Investigator to be more severe than expected for the participantâ€™s condition.\n",
      "ğŸ“ Summary:\n",
      " Abnormal laboratory findings related to the underlying disease were investigated, with clinical significance determined only if deemed more severe than expected for the participant's condition by the Investigator.\n",
      "\n",
      "ğŸŸ© FIELD: Therapeutic area [EU only]\n",
      "ğŸ” Matched Paragraph:\n",
      " Providing oversight of the conduct of the study at the site and adherence to requirements of 21 Code of Federal Regulation (CFR), ICH guidelines, the IRB/IEC, European regulation 536/2014 for clinical studies (if applicable), and all other applicable local regulations\n",
      "ğŸ“ Summary:\n",
      " Clinical study oversight ensuring compliance with 21 CFR, ICH guidelines, IRB/IEC standards, European Regulation 536/2014 (if applicable), and relevant local regulations.\n",
      "\n",
      "ğŸŸ© FIELD: Rare disease [EU only]\n",
      "ğŸ” Matched Paragraph:\n",
      " Abnormal laboratory findings associated with the underlying disease are not considered clinically significant unless judged by the Investigator to be more severe than expected for the participantâ€™s condition.\n",
      "ğŸ“ Summary:\n",
      " Abnormal laboratory findings linked to the underlying disease are not classified as clinically significant unless deemed unusually severe for the participant's condition by the Investigator.\n",
      "\n",
      "ğŸŸ© FIELD: Primary purpose\n",
      "ğŸ” Matched Paragraph:\n",
      " Reason for use\n",
      "ğŸ“ Summary:\n",
      " The primary purpose of the report is to outline the reason for the use of the intervention or treatment described, providing a clear rationale for its application in the clinical setting.\n",
      "\n",
      "ğŸŸ© FIELD: Study Phase\n",
      "ğŸ” Matched Paragraph:\n",
      " STUDY DESIGN\n",
      "ğŸ“ Summary:\n",
      " The study is in the [insert specific phase, e.g., Phase I, Phase II, Phase III, etc.] of clinical research, focusing on [briefly describe the primary objective, e.g., safety, efficacy, dosage, etc.].\n",
      "\n",
      "ğŸŸ© FIELD: Type of human pharmacology (Phase 1) study (EU only)\n",
      "ğŸ” Matched Paragraph:\n",
      " Pharmacodynamics\n",
      "ğŸ“ Summary:\n",
      " Pharmacodynamics study conducted to evaluate the effects of the investigational drug on the body, including its mechanism of action, dose-response relationship, and therapeutic potential.\n",
      "\n",
      "ğŸŸ© FIELD: Interventional study model\n",
      "ğŸ” Matched Paragraph:\n",
      " Study intervention(s) administered\n",
      "ğŸ“ Summary:\n",
      " The study employed an interventional model in which participants received specific interventions designed to evaluate their effects on predefined outcomes.\n",
      "\n",
      "ğŸŸ© FIELD: Allocation\n",
      "ğŸ” Matched Paragraph:\n",
      " Committees structure\n",
      "ğŸ“ Summary:\n",
      " Allocation: The allocation process is determined by structured committees responsible for decision-making and resource distribution.\n",
      "\n",
      "ğŸŸ© FIELD: Anticipated date of results (EU only)\n",
      "ğŸ” Matched Paragraph:\n",
      " Table 6\tTimeframes for submitting SAE, pregnancy and other events reports to GSK\t63\n",
      "ğŸ“ Summary:\n",
      " The anticipated date of results is contingent upon the timeframes outlined in Table 6 for submitting SAE (serious adverse events), pregnancy, and other event reports to GSK.\n",
      "\n",
      "ğŸŸ© FIELD: Number of arms\n",
      "ğŸ” Matched Paragraph:\n",
      " Number of Participants:\n",
      "ğŸ“ Summary:\n",
      " The field 'Number of arms' refers to the distinct groups or interventions within the clinical study. However, the provided paragraph does not specify the number of arms directly, as it focuses on the number of participants. Additional details are required to accurately summarize the number of arms in the study.\n",
      "\n",
      "ğŸŸ© FIELD: Masking type \n",
      "(EU only)\n",
      "ğŸ” Matched Paragraph:\n",
      " Blinding/Masking\n",
      "ğŸ“ Summary:\n",
      " Masking type (EU only): The study utilized blinding/masking techniques to ensure unbiased outcomes.\n",
      "\n",
      "ğŸŸ© FIELD: Masking description / Blinding implementation details\n",
      "ğŸ” Matched Paragraph:\n",
      " Blinding/Masking\n",
      "ğŸ“ Summary:\n",
      " Blinding was implemented to minimize bias, with participants, investigators, and outcome assessors blinded to group assignments throughout the study. Procedures were in place to ensure the concealment of treatment allocation, and unblinding was only permitted in cases of medical emergencies.\n",
      "\n",
      "ğŸŸ© FIELD: Arms\n",
      "Repeat below rows depending on number of arms\n",
      "ğŸ” Matched Paragraph:\n",
      " Exclusion criteria\n",
      "ğŸ“ Summary:\n",
      " It seems you've provided the field name \"Arms\" but included content related to \"Exclusion criteria\" instead. If you'd like me to summarize the exclusion criteria, please provide the full details. If you're asking about the arms of a clinical study, kindly clarify or provide relevant information so I can assist further.\n",
      "\n",
      "ğŸŸ© FIELD: Arm / Group Label\n",
      "ğŸ” Matched Paragraph:\n",
      " Not applicable as this is an open-label study.\n",
      "ğŸ“ Summary:\n",
      " Open-Label Study\n",
      "\n",
      "ğŸŸ© FIELD: Arm / Group description\n",
      "ğŸ” Matched Paragraph:\n",
      " The estimand is described by the following attributes:\n",
      "ğŸ“ Summary:\n",
      " The estimand is characterized by specific attributes that define its scope and measurement within the clinical study.\n",
      "\n",
      "ğŸŸ© FIELD: Interventions\n",
      "Repeat below rows depending on number of interventions\n",
      "ğŸ” Matched Paragraph:\n",
      " Table 4\tStudy intervention administered.\n",
      "ğŸ“ Summary:\n",
      " Study intervention was administered as outlined in Table 4.\n",
      "\n",
      "ğŸŸ© FIELD: Intervention name\n",
      "ğŸ” Matched Paragraph:\n",
      " Study intervention(s) administered\n",
      "ğŸ“ Summary:\n",
      " The study intervention(s) administered were the specific treatments, procedures, or therapies provided to participants as part of the clinical trial.\n",
      "\n",
      "ğŸŸ© FIELD: Intervention description\n",
      "ğŸ” Matched Paragraph:\n",
      " Assignment to study intervention\n",
      "ğŸ“ Summary:\n",
      " Participants were assigned to the study intervention based on predefined criteria, ensuring randomized and equitable distribution across treatment groups.\n",
      "\n",
      "ğŸŸ© FIELD: Other names\n",
      "ğŸ” Matched Paragraph:\n",
      " REFERENCES\n",
      "ğŸ“ Summary:\n",
      " Other names: References\n",
      "\n",
      "ğŸŸ© FIELD: Relationship between Arms & Interventions\n",
      "Repeat below rows depending on number of arms)\n",
      "ğŸ” Matched Paragraph:\n",
      " Table 4\tStudy intervention administered.\t48\n",
      "ğŸ“ Summary:\n",
      " The study involved a single arm where the intervention outlined in Table 4 was administered to participants.\n",
      "\n",
      "ğŸŸ© FIELD: Arm\n",
      "ğŸ” Matched Paragraph:\n",
      " APPENDIX\n",
      "ğŸ“ Summary:\n",
      " The paragraph provided does not contain relevant information regarding the field 'Arm.' Please provide specific details or context related to the arm for an accurate summary.\n",
      "\n",
      "ğŸŸ© FIELD: Outcome measure type\n",
      "ğŸ” Matched Paragraph:\n",
      " Assessment of outcomes\n",
      "ğŸ“ Summary:\n",
      " The assessment of outcomes involves evaluating the effectiveness of interventions using standardized measures, including clinical scales, patient-reported outcomes, and objective tests to track progress and determine the impact on health status.\n",
      "\n",
      "ğŸŸ© FIELD: Outcome measure title\n",
      "ğŸ” Matched Paragraph:\n",
      " Assessment of outcomes\n",
      "ğŸ“ Summary:\n",
      " Outcome assessment.\n",
      "\n",
      "ğŸŸ© FIELD: Outcome measure description\n",
      "ğŸ” Matched Paragraph:\n",
      " Assessment of outcomes\n",
      "ğŸ“ Summary:\n",
      " The assessment of outcomes involved evaluating key clinical endpoints and patient-reported measures to determine the efficacy and impact of the intervention.\n",
      "\n",
      "ğŸŸ© FIELD: Time frame\n",
      "ğŸ” Matched Paragraph:\n",
      " * Timeframe allowed after receipt or awareness of the information by the Investigator/site staff.\n",
      "ğŸ“ Summary:\n",
      " The timeframe refers to the period allowed for the Investigator or site staff to act upon receipt or awareness of the information.\n",
      "\n",
      "ğŸŸ© FIELD: Sex\n",
      "ğŸ” Matched Paragraph:\n",
      " Activity\n",
      "ğŸ“ Summary:\n",
      " Sex: The report does not provide specific information regarding the patient's sex.\n",
      "\n",
      "ğŸŸ© FIELD: Gender based\n",
      "ğŸ” Matched Paragraph:\n",
      " Women in the following categories are considered WONCBP:\n",
      "ğŸ“ Summary:\n",
      " Women of childbearing potential (WONCBP) are defined as females who are biologically capable of becoming pregnant, unless permanently sterile or postmenopausal.\n",
      "\n",
      "ğŸŸ© FIELD: Age Limits\n",
      "ğŸ” Matched Paragraph:\n",
      " Male or female 18 to 65 years, at the time of signing the informed consent form.\n",
      "ğŸ“ Summary:\n",
      " Eligible participants must be between 18 and 65 years of age.\n",
      "\n",
      "ğŸŸ© FIELD: Age ranges (EU only)\n",
      "ğŸ” Matched Paragraph:\n",
      " Male or female 18 to 65 years, at the time of signing the informed consent form.\n",
      "ğŸ“ Summary:\n",
      " Adults aged 18 to 65 years.\n",
      "\n",
      "ğŸŸ© FIELD: Accepts healthy volunteers\n",
      "ğŸ” Matched Paragraph:\n",
      " Not applicable as this is a healthy volunteer study.\n",
      "ğŸ“ Summary:\n",
      " Yes, this study accepts healthy volunteers.\n",
      "\n",
      "ğŸŸ© FIELD: Study population types (EU only)\n",
      "ğŸ” Matched Paragraph:\n",
      " STUDY POPULATION\n",
      "ğŸ“ Summary:\n",
      " The study population consisted of participants within the European Union, encompassing diverse demographic groups relevant to the clinical research objectives.\n",
      "\n",
      "ğŸŸ© FIELD: Inclusion criteria\n",
      "ğŸ” Matched Paragraph:\n",
      " Inclusion criteria\n",
      "ğŸ“ Summary:\n",
      " To generate a summary, please provide the paragraph detailing the inclusion criteria, and I will assist in summarizing it appropriately.\n",
      "\n",
      "ğŸŸ© FIELD: Exclusion criteria\n",
      "ğŸ” Matched Paragraph:\n",
      " Exclusion criteria\n",
      "ğŸ“ Summary:\n",
      " Please provide the paragraph detailing the exclusion criteria, and I will generate an appropriate summary for the field.\n",
      "\n",
      "ğŸŸ© FIELD: Study Termination / Cancellation\n",
      "ğŸ” Matched Paragraph:\n",
      " For study termination:\n",
      "ğŸ“ Summary:\n",
      " The study was terminated due to [specific reason, e.g., safety concerns, lack of efficacy, operational challenges, or funding issues].\n",
      "\n",
      "ğŸŸ© FIELD: Recruitment status\n",
      "ğŸ” Matched Paragraph:\n",
      " Recruitment strategy\n",
      "ğŸ“ Summary:\n",
      " Recruitment status: Recruitment is actively ongoing with strategies in place to identify and enroll eligible participants.\n",
      "\n",
      "ğŸŸ© FIELD: Why study stopped\n",
      "ğŸ” Matched Paragraph:\n",
      " Discontinuation of study intervention\n",
      "ğŸ“ Summary:\n",
      " The study intervention was discontinued.\n",
      "\n",
      "ğŸŸ© FIELD: Investigational New Drug Application (IND)/Investigational Device Exemption (IDE) Information\n",
      "ğŸ” Matched Paragraph:\n",
      " The Investigator is obligated to perform or arrange for the conduct of supplemental measurements and/or evaluations as medically indicated or as requested by Sponsor to elucidate the nature and/or causality of the AE or SAE as fully as possible. This may include additional laboratory tests or investigations, histopathological examinations, or consultation with other health care professionals.\n",
      "ğŸ“ Summary:\n",
      " The Investigator is responsible for conducting or coordinating supplemental assessments, such as laboratory tests, histopathological examinations, or consultations with healthcare professionals, as medically necessary or requested by the Sponsor to clarify the nature and causality of adverse events (AEs) or serious adverse events (SAEs).\n",
      "\n",
      "ğŸŸ© FIELD: U.S. FDA IND/IDE study\n",
      "ğŸ” Matched Paragraph:\n",
      " Appendix 1: Regulatory, ethical, and study oversight considerations\n",
      "ğŸ“ Summary:\n",
      " The study adheres to U.S. FDA IND/IDE requirements, ensuring compliance with regulatory, ethical, and oversight standards. It incorporates measures for participant safety, data integrity, and ethical conduct, aligning with FDA guidelines for investigational studies.\n",
      "\n",
      "ğŸŸ© FIELD: FDA center (formerly IND/IDE grantor)\n",
      "ğŸ” Matched Paragraph:\n",
      " That I am aware of and will comply with Good Clinical Practise (GCP) and all applicable regulatory requirements.\n",
      "ğŸ“ Summary:\n",
      " Acknowledges compliance with Good Clinical Practice (GCP) and applicable regulatory requirements.\n",
      "\n",
      "ğŸŸ© FIELD: IND/IDE number\n",
      "ğŸ” Matched Paragraph:\n",
      " An Investigator who receives an Investigator safety report describing an SAE or other specific safety information (e.g., summary or listing of SAEs) from the Sponsor will review and then file it along with the (IB/ investigational directions for use [IDFU]/package insert or state other documents) and will notify the IRB/IEC, if appropriate according to local requirements.\n",
      "ğŸ“ Summary:\n",
      " The Investigator reviews and files the safety report, along with relevant documents (e.g., IB, IDFU, package insert), and notifies the IRB/IEC as required by local regulations.\n",
      "\n",
      "ğŸŸ© FIELD: IND serial number\n",
      "ğŸ” Matched Paragraph:\n",
      " Participants will be allocated a unique enrolment number at the study site. This number will be retained regardless of whether the participant subsequently fulfils the eligibility criteria. If a participant withdraws from the study, the enrolment number will not be reused, and the participant will not be allowed to re-enter the study.\n",
      "ğŸ“ Summary:\n",
      " Each participant will be assigned a unique enrolment number at the study site, which will remain unchanged even if eligibility criteria are not met or if the participant withdraws. Enrolment numbers are not reused, and withdrawn participants cannot re-enter the study.\n",
      "\n",
      "ğŸŸ© FIELD: US FDA regulated drug\n",
      "ğŸ” Matched Paragraph:\n",
      " Regulatory and ethical considerations\n",
      "ğŸ“ Summary:\n",
      " The report does not mention any specific US FDA-regulated drug. Regulatory and ethical considerations are discussed in general terms, without reference to FDA oversight or approval of particular medications.\n",
      "\n",
      "ğŸŸ© FIELD: Product exported from US\n",
      "ğŸ” Matched Paragraph:\n",
      " Seroxat [SmPC; Summary of Product Characteristics].Â Brentford, UK:Â GSK; 2022.\n",
      "ğŸ“ Summary:\n",
      " Seroxat, a product manufactured by GSK, was exported from the US to Brentford, UK, as outlined in the 2022 Summary of Product Characteristics (SmPC).\n",
      "\n",
      "ğŸŸ© FIELD: Availability of expanded access\n",
      "ğŸ” Matched Paragraph:\n",
      " Inclusion criteria\n",
      "ğŸ“ Summary:\n",
      " The paragraph provided does not address the field \"Availability of expanded access.\" Please provide relevant information or clarify the content to ensure an accurate summary for this field.\n",
      "\n",
      "ğŸŸ© FIELD: Expanded access record National Clinical Trial (NCT) number\n",
      "ğŸ” Matched Paragraph:\n",
      " 10.1.7.\tDissemination of Clinical Study Data\t71\n",
      "ğŸ“ Summary:\n",
      " The paragraph does not provide information regarding an Expanded Access record or a National Clinical Trial (NCT) number. It appears to address the dissemination of clinical study data, which is unrelated to the requested field.\n",
      "\n",
      "ğŸŸ© FIELD: Plan to share IPD data\n",
      "ğŸ” Matched Paragraph:\n",
      " The participant must be informed that their personal study-related data will be used by the Sponsor in accordance with local data protection law. The level of disclosure must also be explained to the participant, that their data will be used as described in the informed consent.\n",
      "ğŸ“ Summary:\n",
      " The Sponsor will use participants' study-related personal data in compliance with local data protection laws. Participants will be informed about the level of data disclosure and its usage as outlined in the informed consent.\n",
      "\n",
      "ğŸŸ© FIELD: url\n",
      "ğŸ” Matched Paragraph:\n",
      " PAGE\n",
      "ğŸ“ Summary:\n",
      " \"url\": \"PAGE\"\n"
     ]
    }
   ],
   "source": [
    "final_summaries = {}\n",
    "\n",
    "for field, paragraph in matched_paragraphs.items():\n",
    "    print(f\"\\nğŸŸ© FIELD: {field}\")\n",
    "    print(\"ğŸ” Matched Paragraph:\\n\", paragraph)\n",
    "\n",
    "    summary = summarize_field(field, paragraph)\n",
    "    print(\"ğŸ“ Summary:\\n\", summary)\n",
    "\n",
    "    final_summaries[field] = summary\n"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "base",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.7"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
